01363nas a2200253   4500000000100000008004100001260001300042653002400055653002300079653001600102653001300118653001200131653002500143653003100168653002500199653001800224653002400242100001700266245004500283300001000328490000700338520075000345022001401095       1989                            d  c1989 Sep10aAntigens, Bacterial10aBacterial Vaccines10aBCG Vaccine10aEpitopes10aleprosy10aMycobacterium leprae10aMycobacterium tuberculosis10aRecombinant Proteins10aT-Lymphocytes10aVaccines, Synthetic1 aKaufmann S H00aLeprosy and tuberculosis vaccine design.  a251-70 v403 a<p>Tuberculosis and leprosy are bacillary infectious diseases which cause severe global health problems with approximately 50 to 60 million people suffering from tuberculosis and 10 to 15 million from leprosy. In the developing countries the currently available vaccine, Bacille Calmette-Guérin (BCG) was found to be less effective than originally thought. This disappointment, as well as recent achievements in biotechnology, has led several researchers to embark on novel avenues towards a rational vaccine design. This strategy stems from the idea that protective antigens exist which can be identified by immunological methods, expressed as recombinant gene products, and administered in a way that induces a protective T cell response.</p>  a0177-2392